Kamada Ltd.

Hello, and welcome to the Commodot Limited third quarter 2021 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Bob Yedit with LifeSci Advisors. Please go ahead, Bob.

Thank you, and thank you all for joining us. This is Bob Yetted from LifeSci Advisors. Joining me from Kamada are Amir London, Chief Executive Officer, and Jaime Orlev, Chief Financial Officer. Earlier this morning, Kamada announced a strategic transformational transaction, positioning the company as a global leader in plasmid-derived hyperimmune market through the acquisition of a portfolio of four FDA-approved plasmid-derived commercial products from Sayall Therapeutics, a privately held pharmaceutical company, as well as its financial results for the three and nine months ended September 30th, 2021. If you have not received these news releases, please go to the investor's page of the company's website. Before we begin, I'd like to caution the comments made during this conference called by management will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Comida. I encourage you to review the company's filings with securities and exchange commissions, including without limitation the company's forms 20F and 6K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, Monday, November 22, 2021. Comida undertakes no obligation to revise or update any statements to reflect these events or circumstances after the date of this conference call. With those prepared remarks, it's my pleasure to turn the call over to Amir London, CEO. Amir?

Thank you, Bob. My thanks also to our investors and analysts for your interest in Kamada and for participating in today's call. I and all of us at Kamada are thrilled to announce this morning the strategic transformational transaction positioning Kamada as a global leader in the plasma-derived hyperimmune market through the acquisition of a portfolio of four FDA-approved plasma-derived hyperimmune commercial products from Cell Therapeutics. Before I continue to provide you with an overview of this strategic transaction, which is a significant growth catalyst for Kamada, I will ask Jaime to provide the key details around our financial results for the third quarter and the nine months ended September 30th. Jaime, please.